H.C. Wainwright Reiterates Buy Rating on Iterum Therapeutics (ITRM)

September 10, 2024 6:44 AM UTC Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $5.00 price target on Iterum Therapeutics (NASDAQ: ITRM).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login